March 2, 2021Open Access

Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I

Key Points

Key points are not available for this paper at this time.

Abstract

In patients with platinum-resistant EOC, MIRV did not result in a significant improvement in PFS compared with chemotherapy. Secondary endpoints consistently favored MIRV, particularly in patients with high FRα expression. MIRV showed a differentiated and more manageable safety profile than chemotherapy.

Perguntar à IA

Bookmark

View Full Paper

Cite This Study

Moore et al. (Tue,) studied this question.

synapsesocial.com/papers/69dacab64e9a02dbaa6848a1 https://doi.org/https://doi.org/10.1016/j.annonc.2021.02.017

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FRα-targeting antibody-drug conjugate mirvetuximab soravtansine2017 · 140 citations
2FORWARD I: A Phase III Study of Mirvetuximab Soravtansine Versus Chemotherapy in Platinum-Resistant Ovarian Cancer2018 · 74 citations
3Antibody-Drug Conjugates Designed to Eradicate Tumors with Homogeneous and Heterogeneous Expression of the Target Antigen2006 · 474 citations
4A sharper Bonferroni procedure for multiple tests of significance1988 · 4,745 citations
5Expression of folate binding protein as a prognostic factor for response to platinum-containing chemotherapy and survival in human ovarian cancer1998 · 163 citations

Perguntar à IA

Bookmark

View Full Paper